VBI Vaccines (Nasdaq: VBIV) (“VBI”) is scheduled to present at the  Tenth Annual Immunotherapy and Vaccine (“IMVACS”) Summit on Wednesday, August 26th, 2015 at 4:30 PM ET. The event is being held at the Marriott Long Wharf Hotel in Boston, MA.

Adam Buckley, VBI’s Vice President of Business Development, will deliver a presentation entitled, Enveloped Virus-Like Particles, A Novel and Immunogenic Expression Platform. Mr. Buckley’s presentation will provide an overview of VBI’s eVLP Platform and an update on the progress of the company’s cytomegalovirus (“CMV”) vaccine program. Download the IMVACS Presentation“VBI, with its contractors, is now manufacturing its CMV vaccine candidate at a 50L production scale with high yields and purity,” said Mr. Buckley. “Planned human doses and formulations have met internal targets for stability, consistency, and potency. Formal toxicology studies are underway and we anticipate beginning a human Phase I clinical trial in the first quarter of 2016.”

VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely resemble the structure of enveloped viruses. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone. VBI is focused first on applying its eVLP technology to develop a prophylactic CMV vaccine.

The IMVACS Summit brings together a global audience of vaccine researchers and developers with coverage of adjuvants, vaccines, and immunotherapy technologies. For more information, visit: http://bit.ly/imvacs-2015

Event Details

  • Event: Tenth Annual Immunotherapies and Vaccine (“IMVACS”) Summit
  • Date: Wednesday, August 26th, 2015
  • Time: 4:30 PM ET
  • Location: Marriott Long Wharf Hotel in Boston, MA